
In a first-in-man trial, 32 patients with alcohol-related acute-on-chronic liver failure (ACLF) were randomly assigned to receive treatment with DIALIVE, an extracorporeal liver dialysis device, or the current standard of care for up to 5 days. The trial demonstrated that DIALIVE was safe, with no serious adverse effects reported. The DIALIVE group showed reduced severity of endotoxaemia, improved albumin function, and faster resolution of ACLF compared to the standard care group. Additionally, biomarkers of systemic inflammation, including IL-8, were improved in the DIALIVE group.
Like
Save
Share